open access

Vol 52, No 5 (2018)
Original research articles
Submitted: 2018-04-19
Get Citation

Lymphocyte populations and their change during five-year glatiramer acetate treatment

Zbyšek Pavelek, Oldřich Vyšata, Lukáš Sobíšek, Blanka Klímová, Ctirad Andrýs, Doris Vokurková, Radka Mazurová, Pavel Štourač, Martin Vališ
DOI: 10.1016/j.pjnns.2018.08.001
·
Neurol Neurochir Pol 2018;52(5):587-592.

open access

Vol 52, No 5 (2018)
Original research articles
Submitted: 2018-04-19

Abstract

Background

The goal of this study was to determine the characteristics that are affected in patients treated with glatiramer acetate (GA).

Methods

A total of 113 patients were included in this study. Patients were treated with glatiramer acetate (subcutaneous injection, 20 mg, each day). Peripheral blood samples were obtained just prior to treatment as well as 5 years after GA treatment. All the calculations were performed with the statistical system R (r-project.org).

Results

After 5 years of treatment, a significant decrease was found in the absolute and relative CD3+/CD69+ counts, the absolute and relative CD69 counts, the relative CD8+/CD38+ count and the relative CD38 count. A significant increase was found in the absolute and relative CD5+/CD45RA+ counts and the absolute CD5+/CD45RO+ count after 5 years of treatment.

Conclusion

This study presents some parameters that were affected by long-term GA treatment.

Abstract

Background

The goal of this study was to determine the characteristics that are affected in patients treated with glatiramer acetate (GA).

Methods

A total of 113 patients were included in this study. Patients were treated with glatiramer acetate (subcutaneous injection, 20 mg, each day). Peripheral blood samples were obtained just prior to treatment as well as 5 years after GA treatment. All the calculations were performed with the statistical system R (r-project.org).

Results

After 5 years of treatment, a significant decrease was found in the absolute and relative CD3+/CD69+ counts, the absolute and relative CD69 counts, the relative CD8+/CD38+ count and the relative CD38 count. A significant increase was found in the absolute and relative CD5+/CD45RA+ counts and the absolute CD5+/CD45RO+ count after 5 years of treatment.

Conclusion

This study presents some parameters that were affected by long-term GA treatment.

Get Citation

Keywords

Multiple sclerosis, Lymphocytes, Glatiramer acetate, Parameters, Treatment

About this article
Title

Lymphocyte populations and their change during five-year glatiramer acetate treatment

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 52, No 5 (2018)

Pages

587-592

DOI

10.1016/j.pjnns.2018.08.001

Bibliographic record

Neurol Neurochir Pol 2018;52(5):587-592.

Keywords

Multiple sclerosis
Lymphocytes
Glatiramer acetate
Parameters
Treatment

Authors

Zbyšek Pavelek
Oldřich Vyšata
Lukáš Sobíšek
Blanka Klímová
Ctirad Andrýs
Doris Vokurková
Radka Mazurová
Pavel Štourač
Martin Vališ

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl